Newsroom | 93150 results

NUEVA YORK--(BUSINESS WIRE)--Blue Matter tiene el orgullo de anunciar que ha establecido un área de práctica que prestará exclusivamente servicios a los clientes en investigación y desarrollo (I+D) biofarmacéutico. La dirección de esta práctica estará a cargo de Tara Austraat-Churik, una socia que se incorporó a la firma en septiembre de 2025. Tara Austraat-Churik tiene más de 20 años de experiencia en servicios a los clientes del sector de las ciencias de la vida. Se ha especializado en las ár...

NEW YORK--(BUSINESS WIRE)--Blue Matter a le plaisir d'annoncer la création d'un domaine d'expertise dédié aux clients du secteur de la recherche et développement biopharmaceutique. Ce domaine est dirigé par l'associée Tara Austraat-Churik, qui a rejoint le cabinet en septembre 2025. Tara Austraat-Churik accompagne les acteurs des sciences de la vie depuis plus de 20 ans. Ses domaines d'expertise comprennent le développement et la mise en œuvre de stratégies, la conception de modèles opérationne...

NEW YORK--(BUSINESS WIRE)--Blue Matter annuncia la creazione di una nuova area di consulenza dedicata ai clienti del settore R&S biofarmaceutico e diretta da Tara Austraat-Churik, partner unitasi a Blue Matter nel settembre 2025. Tara Austraat-Churik vanta un’esperienza di oltre 20 anni al servizio di clienti nel settore delle scienze della vita. Molteplici le sue aree di competenza – sviluppo e implementazione di strategie, progettazione di modelli operativi e organizzativi, ottimizzazione...

NEW YORK--(BUSINESS WIRE)--Blue Matter hat einen neuen Praxisbereich gegründet, der auf die Bedürfnisse von Kunden aus der biopharmazeutischen Forschung und Entwicklung (FuE) ausgerichtet ist. Geleitet wird der Praxisbereich von Tara Austraat-Churik, einer Partnerin, die seit September 2025 für Blue Matter tätig ist. Tara Austraat-Churik ist bereits seit über 20 Jahren für Life-Science-Kunden tätig. Ihre Schwerpunkte sind Strategieentwicklung und -umsetzung, Betriebsmodell- und Organisationsges...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate...

SAN DIEGO--(BUSINESS WIRE)--Allele Biotechnology & Pharmaceuticals, Inc. (Allele), a San Diego-based technology development and cell manufacturing company, today announced its participation in an up to $25.8 million research project with the University of California, San Diego, funded by the Advanced Research Projects Agency for Health (ARPA-H). The project’s goal is to develop a fully functional, patient-specific, 3D bioprinted liver for transplantation. This project is under ARPA-H’s Pers...

ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services (NYSE: GRDN), one of the nation’s leading long-term care (“LTC”) pharmacy services companies, is reiterating its previously announced 2025 guidance and providing its preliminary financial outlook for 2026. The Company expects to continue its low double-digit adjusted EBITDA growth trajectory in 2026, supported by the strength of its operating model and increased visibility into the year ahead, including anticipated drug pricing changes. The C...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2025, and reaffirmed its full year 2026 revenue guidance. Preliminary and unaudited total net sales for the fourth quarter of 2025 are expected to be approximately $14...

ZHUZHOU, China & BOSTON--(BUSINESS WIRE)--Zonsen PepLib Biotech Inc. (“PepLib”) today announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based asset in the field of radioligand therapies (RLTs). Under the agreement, Novartis has obtained an exclusive worldwide license and will be responsible for the development and commercialization activities for the asset. The asset has been developed internally by PepLib to date. Through this transaction...

DUBLIN--(BUSINESS WIRE)--The "CD22 Targeted Therapies Market, Approved Drug Sales, Technology Platforms & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. Report Findings & Highlights: Current & Future Global Market Outlook Insight on CD22 Targeted Approaches Approved Drug Dosage, Price & Sales Insight CD22 Targeted Therapies Development Trends by Region & Indications CD22 Targeted Therapies in Clinical Trials: > 20 Therapies CD22...